US Patent

US9439901 — Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Method of Use · Assigned to Pfizer Inc · Expires 2030-10-21 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds of Formula (A) and (B) for the treatment of diseases, conditions, and/or disorders mediated by sodium-glucose transporter inhibitors.

USPTO Abstract

Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Drugs covered by this patent

Steglatro (ERTUGLIFLOZIN) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2214`	—	Steglatro
`U-2214`	—	Steglatro

Patent Metadata

Patent number: US9439901
Jurisdiction: US
Classification: Method of Use
Expires: 2030-10-21
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.